Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients

• Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation
• Approval based on positive outcomes from largest liver transplant study ever, comparing Zortress plus reduced-exposure tacrolimus to standard tacrolimus
• Under trade name Certican®, the drug was approved by European Health Authorities for use in adult liver transplant patients in the fourth quarter of 2012

View the press release from Novartis or visit the Novartis website or the FDA website for more information.